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acute glomerulonephritis: A multicentric study.
Background. Cationic streptococcal proteinase (erythrotoxin B)
and its precursor, zymogen, are putative nephritogenic antigens.
The present study was designed to test whether serum titers to
these antigens were good markers of streptococcal infection
associated with glomerulonephritis.
Methods. We studied 153 patients (male/female 5 104/49, age
range, 2 to 23 years old) with acute poststreptococcal glomerulo-
nephritis (APSGN) from three countries (Venezuela, Chile and
Argentina). The site of the initial infection was the skin in 84
patients, the throat in 55 patients and was unknown in 14 patients.
In addition, we studied 23 patients (1 to 24 years old) with
streptococcal infection not associated with glomerulonephritis (14
patients with impetigo and 9 patients with pharyngitis). As control
group, 93 healthy individuals (54 males, 2 to 19 years old) were
studied.
Anti-zymogen and anti-proteinase titers were determined in a
single laboratory by ELISA, and the intra- and interassay coeffi-
cients of variation were 5.3% and 8.5%, respectively. ASO titers
and anti-DNAse B titers were also done.
Results. Anti-zymogen titers of 1:800 to 1:3200 had likelihood
ratios (sensitivity/1-specificity) for detection of streptococcal in-
fection in APSGN patients ranging from 2.00 to 44.2 in Argentina,
Chile and Venezuela. Anti-zymogen titers decreased one to two
months after APSGN and they were 1 to 3 log2 dilutions higher
that anti-proteinase titers. Receiver operating characteristic
(ROC) curves showed that anti-zymogen titers were consistently
superior to anti-streptolysin O and anti-DNAse B titers as mark-
ers for streptococcal infection in APSGN.
Conclusions. These results suggest that increased anti-zymogen
antibody titers are the best available marker for streptococcal
infection associated with acute glomerulonephritis.
The identity of the streptococcal antigen(s) believed to
be responsible for acute poststreptococcal glomerulone-
phritis has been the subject of many investigations. Several
potential nephritogens capable of inducing a humoral
immune response have been characterized and localized in
the glomeruli of patients with acute poststreptococcal
glomerulonephritis (APSGN) [reviewed in 1, 2]. Yet the
difficulty in obtaining convincing proof of nephritogenicity
in animal experiments, the likely participation of autoim-
mune reactivity in the disease and the decreasing incidence
of APSGN in industrialized countries have hampered
progress in this field.
In 1945, Elliot [3] published the first ever report on a
zymogen produced by b-hemolytic group A streptococci,
the precursor of a streptococcal proteinase [4, 5]. This
proteinase is identical to the erythrogenic toxin B, subse-
quently described by Gerlach et al [6]. In 1980, in a
collaborative study our groups demonstrated cationic strep-
tococcal antigens in the glomeruli of patients with APSGN
[7], and this material was, in fact, streptococcal proteinase
[8]. In 1993, Poon-King et al [9] determined that strepto-
coccal strains known to be associated with nephritis pro-
duced a plasmin-binding protein that was identified as
zymogen. These findings clearly focused attention on strep-
tococcal zymogen as a putative nephritogen in APSGN.
The charge properties of the proteinase could enable it to
initiate immune complex formation in the glomerular cap-
illary wall [10, 11].
Several preliminary studies have indicated that patients
with APSGN can have elevated levels of serum antibodies
to streptococcal zymogen/proteinase [7, 12–14]. The
present multicentric international study was undertaken to
define how frequently patients with APSGN present ele-
vated serum titers of anti-zymogen antibodies. We con-
clude that anti-zymogen antibody titers are the best avail-
able marker identified to date for streptococcal infections
associated with APSGN.
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METHODS
Patients and controls
Studies were done in 153 patients, 104 males and 49
females, with APSGN hospitalized in tertiary care centers
(102 patients from Hospital Universitario de Maracaibo
and Hospital Central de Valencia, Venezuela; 31 patients
from Hospital Municipal de San Justo, Provincia de Bue-
nos Aires, Argentina; and 20 patients from Hospital Clı´nico
Regional, Universidad Austral, Valdivia, Chile; Table 1).
All these patients had typical APSGN that presented as
acute nephritic syndrome ranging from mild to severe, and
they all had decreased C3 levels. Tests were done to
exclude other causes of glomerulonephritis and all recov-
ered uneventfully. The site location of the original strepto-
coccal infection was the skin in 84 patients and the throat in
55 patients; it was unknown in 14 patients but in these
individuals, recent streptoccocal infection was confirmed by
a $ 2 dilution change in ASO or DNAse B titers at
follow-up. The age range was 2 to 23 years (Table 1).
The control group were 93 healthy children, ranging in
age from 2 to 19 years, selected from the Healthy Children
& Adolescent Clinics of the participating centers with
permission of their parents and guardians (Table 1). In
addition, 14 patients with impetigo and 9 patients with
streptococcal angina who had no evidence of glomerulone-
phritis were also studied. The diagnosis of streptococcal
sore throat was made on clinical grounds (all patients had
fever, painful regional lymphadenopathy and tonsillar exu-
date) and was confirmed in situ by a rapid test for identi-
fication of group A streptococcus in cultures or exudates,
using a rapid colorimetric enzyme-linked immunoabsor-
bent assay (Testpack Strep A plusy; Abbot Laboratories),
as described previously [15]. Identification of M and T
types was not done. To rule out the possibility of subclinical
glomerulonephritis, routine urine and sediment analysis, as
well as serum complement determinations were done
weekly for three to four weeks after the infection in
patients with streptococcal angina.
Serum samples were taken on admission, and one and
two months afterwards in the APSGN patients. One serum
sample was collected from children with impetigo and
controls. Anti-zymogen antibody titers were determined in
all individuals. Anti-proteinase titers were determined in
126 patients with APSGN, 23 patients with streptococcal
infections without nephritis and 93 controls. Anti-strepto-
lysin O titers were done in 78 patients, 23 having infections
without nephritis and 53 controls. Anti-DNAse B titers
were determined in 72 APSGN patients, 23 patients with
streptococcal infection without nephritis and in 53 controls.
Samples were collected at participating centers and
stored at 270°C until they were tested. All tests were done
at the Renal Laboratory in the Hospital Universitario de
Maracaibo.
Consent for the study was obtained from the patients and
controls or from parents or guardians in minors.
Purification and characterization of streptococcal
zymogen and proteinase
Two group A, b-hemolytic strains (Bursello and Mar-3)
isolated from children with APSGN in Maracaibo were
cultured in Todd-Hewitt medium, pH 6.9 at 37°C. This
pre-culture was used to inoculate a mixture of 1000 ml of
Todd-Hewitt dialysate medium and 800 ml of CDM (chem-
ically defined medium) [16], maintained at pH 6.9 at 37°C.
After four hours the pH was reduced to 5.9 and incubated
for a further 12 hours at this pH with regular addition of
glucose. A pH of 5.9 retarded growth but greatly enhanced
production of zymogen by the streptococci [6]. Sodium
azide (final concentration 0.1%) and sodium tetrathionate
(final concentration 5 mM) were added to the supernatant
to prevent contamination and to (reversibly) stabilize the
zymogen. Subsequent conversion to active proteinase,
when desired, was induced by the addition of 10 mM
mercaptoethanol. The supernatant was concentrated 100-
to 500-fold by positive pressure ultrafiltration in an Amicon
cell using a YM10 membrane. Further purification was
performed chromatographically: 5 to 20 mg portions of
zymogen/proteinase were applied to a Mono S cation
exchange column (Pharmacia HR 5/5). The column was
equilibrated in 3.5 mm MES buffer and a gradient of up to
250 mm was run. The fractions were examined in SDS-
PAGE gel electrophoresis (non-reducing conditions). In-
tact zymogen migrated as a 43 kD band, active proteinase
as a 30 kD band. Isoelectric points (pI) were measured by
focusing in a flat bed gel system; zymogen focused at pH 8.3
and proteinase at pH 9.0.
Determination of anti-zymogen and anti-proteinase levels
in serum
Serum concentrations of antibody to both zymogen and
proteinase were measured in an ELISA as follows: 120 ml
Table 1. General characteristics of the individuals in the study
N (males/females)
Age in years
mean (range)
Site of infection
Throat Skin UD
Venezuela
APSGN 102 (67/35) 8.8 (2–23) 39 58 5
Strep sore throat 9 (3/6) 7.3 (2–11) 9 — —
Controls 61 (41/20) 9.4 (6–18) — — —
Chile
APSGN 20 (16/4) 7.5 (2–22) 2 11 7
Impetigo 14 (12/2) 8.7 (1–24) 14 — —
Controls 10 (7/3) 8.8 (1–24) — — —
Argentina
APSGN 31 (21/10) 8.8 (3–14) 14 15 2
Controls 22 (16/6) 8.8 (1–19) — — —
All
APSGN 153 (104/49) 8.2 (2–23) 55 84 14
Strep infection 23 (15/8) 7.9 (1–24) 9 14 —
Controls 93 (64/29) 9.2 (2–19) — — —
General characteristics of the patients and control children. Abbrevia-
tions are: APSGN, acute poststreptoccal glomerulonephritis; UD, unde-
fined. Age differences are not statistically significant.
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of purified streptococcal zymogen or proteinase (2.5 mg/ml)
in carbonate buffer (pH 9.5) were placed in each microtiter
plate well, incubated for one hour at room temperature and
overnight at 4°C. Then the wells were washed five times
with PBS containing 0.05% tween 20. For testing, 100 ml of
blanks or samples, diluted 1:50 to 1:25,600 in PBS contain-
ing 2% Tween 20 and 1% gelatine, were introduced to the
wells and incubated for one hour at room temperature,
before washing with five changes of PBS.
Afterwards, 100 ml of peroxidase conjugated affinity
purified goat anti-human IgG and IgM (0.08 mg/ml) (min-
imal cross reaction with bovine serum proteins; Accurate
Chemical and Scientific Co., USA) were added, incubated
for one hour at 37°C and washed five times with buffer.
Thereafter, 100 ml of substrate (o-phenylenediamine, 0.5
mg/ml in PBS containing methanol and H2O2) were added
and incubated for 15 minutes. Finally, the reaction was
stopped by adding 100 ml of 1 N HCl and the optical density
was read at 490 hm in a spectrophotometer (Plate reader
7500; Cambridge Technology, USA). The antibody titer in
each serum sample was defined as the highest dilution
giving an optical density above 0.100. Results were ex-
pressed as 1:dilution or log2 of 1:dilution.
Intra-assay and interassay variation coefficients were
5.3% and 8.5%, respectively.
There is cross reactivity between proteinase (30 kD, pI
9.0) and its precursor, zymogen (43 kD. pI 8.3). Zymogen is
antigenically superior to proteinase [12].
Other antistreptococcal antibodies
Commercially available kits were used for determination
of anti-streptolysin O (ASO) titers (Human Gesellschaft
fu¨r Biochemica und Diagnostica mbH, Taunusstein, Ger-
many) and anti-DNAse B titers (Streptonase-B; Wampole
Laboratories, Cranbury, NJ, USA).
Calculations and statistical analysis
Statistical comparisons between patient groups (admis-
sion samples) and controls, as well as between countries,
were done after logarithmically transforming the dilution
titers to the base 2. Significant differences (P , 0.05) were
tested using non-parametric Kruskal-Wallis tests followed
by Dunn’s multiple comparison post-tests.
The sensitivity (true positive rate, TPR) of a given (x)
antibody titer for the detection of nephritogenic strepto-
coccal infection was calculated assuming that all cases of
APSGN had, by definition, a nephritogenic streptococcal
infection (see above in the “Patients and controls” section).
The TPR represents the proportion of patients with
APSGN who had an antibody titer equal to or higher than
a determined cutoff point:
TPRx titer (%) 5 (number APSGN patients with
$ x titer)/total number of APSGN patients.
The specificity (true negative rate, TNR) of an antibody
titer was calculated assuming that control individuals did
not have streptococcal infection. The TNR represents the
proportion of control individuals who had an antibody titer
below a determined cutoff point:
TNRx titer ~%! 5 ~number of control subjects with
, x titer)/total number of control individuals
Likelihood ratios ~LR!x titer 5
~TPRx titer!/~1 2 TNRx titer!
To determine both the positive and negative predictive
values made using prior probability of disease (pD), esti-
mates were calculated with the following formulas:
Predictive value positive 5 ~TPR 3 pD!/~TPR 3 pD!
1 @~1 2 TNR! 3 ~1 2 pD!#
Predictive value negative 5 ~TNR 3 1 2 pD!/~TNR
3 1 2 pD) 1 @~1 2 TPR! 3 pD!]
Comparison of the usefulness of ASO, anti-DNAse B,
anti-proteinase and anti-zymogen titers to identify nephri-
tis-causing streptococcal infection was done on the data
from Venezuela (adequate numbers of all four antibody
tests) by generating Receiver Operating Characteristics
(ROC) curves.
RESULTS
The general characteristics of the children in the study
are shown in Table 1. The mean ages of the patients with
APSGN from all three countries were comparable to those
in patients with streptococcal infection without nephritis
and control individuals.
Table 2 shows the anti-streptococcal antibody titers of
the patients with APSGN (on admission), streptococcal
infections without nephritis and healthy controls. Anti-
zymogen titers were significantly higher in APSGN patients
from Chile (Chile vs. Venezuela 5 P , 0.01; Chile vs.
Argentina 5 P , 0.001; Argentina vs. Venezuela 5 P .
0.05), however, the levels in the control groups did not
show a geographical difference (Table 2). Anti-zymogen
titers of APSGN sera were significantly higher (P , 0.001)
than the titers in corresponding control groups. In addition,
anti-zymogen titers in APSGN patients were also signifi-
cantly higher than the titers found in patients with strepto-
coccal sore throat (Venezuela, P , 0.001) and impetigo
(Chile, P , 0.05). Figure 1 shows the individual values in
each of the three centers.
Patients with impetigo had significantly higher anti-
zymogen serum titers than patients with streptococcal
pharyngitis (none of these patients had nephritis; Table 2,
P 5 0.0005). However, there were no significant differences
between the anti-zymogen titers in patients with glomeru-
lonephritis associated with impetigo (log2 anti-zymogen
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titers 5 11.97 6 1.639) and the patients with glomerulone-
phritis associated with streptococcal sore throat (log2 anti-
zymogen titers 5 11.07 6 1.431).
Serum reactivity against streptococcal proteinase was
tested in 126 patients with APSGN, 23 patients with
streptococcal infection without nephritis (9 patients with
streptococcal sore throat and 14 patients with impetigo)
and in 91 controls (Table 2). The control (baseline) values
were the same as those found in anti-zymogen determina-
tions; however, the titers of anti-proteinase in APSGN
patients were, in general, 1 log titer lower than the titers of
its precursor (zymogen).
Anti-streptolysin O titers were not statistically different
in Venezuela and Chile (P . 0.05) and therefore they are
shown together in Figure 2A. ASO titers were higher in the
APSGN patients with respect to controls in Venezuela
(P , 0.001) but not in Chile, and they were comparable in
patients with streptococcal infection with and without
nephritis (Table 2 and Fig. 2A).
Anti-DNAse B titers were higher in APSGN patients in
Venezuela than in Chile (P , 0.05, Table 2). Anti-DNAse
B titers were also higher in APSGN patients than in
controls in Venezuela (P , 0.001), but in Chile the DNAse
B titers did not differ significantly between controls and
patients with APSGN and impetigo (Table 2). Individual
values of anti-DNAse B titers in Venezuela and Chile are
shown in Figure 2, B and C.
The results of serial determinations of anti-zymogen
titers in APSGN patients are shown in Figure 3; serial
determinations of anti-proteinase (not shown) revealed
essentially the same pattern.
Table 3 shows the number of patients and controls with
selected cutoff antibody titers for each of the four assays.
The likelihood ratios for anti-zymogen and anti-proteinase
serum titers are shown in Table 4.
ROC curves for each of the four assays in samples from
Venezuela, where adequate numbers of sera were col-
lected, are shown in Figure 4.
DISCUSSION
The association of group A streptococcal infection with
glomerulonephritis is well known but there is no agreement
on the characteristic(s) that make a streptococcus capable
of causing nephritis. Therefore, at the present time, the
“gold standard” of nephritogenicity of a streptococcus is
simply the development of glomerulonephritis. The assess-
ment of antibody tests to detect nephritogenic streptococ-
cal infection, depends on the study of cases in which both
the diagnosis of acute glomerulonephritis and streptococcal
infection are reasonably assured. Our patients from the
three participating centers were carefully studied; they all
had classical clinical pictures and laboratory findings con-
sistent with these diagnoses. In 14 patients in which the
original site of streptococcal infection was unknown, there
was clear serological evidence of recent streptococcal in-
fection.
In a preliminary study, antibody reactivity to streptococ-
cal zymogen and proteinase was found in both the IgG and
IgM fractions of patients with streptococcal infections, and
a combination of positive results was of most diagnostic
value [12]. Consequently, the ELISA test developed in this
study was designed to detect antibodies of the IgG and IgM
classes. The streptococcal zymogen (43 kD, pI 8.3) is
antigenically superior to its breakdown product, proteinase
(30 kD, pI 9.0), and therefore, it could be expected that
zymogen will bind virtually all antibodies directed to pro-
teinase plus an antibody population directed to the unique
part of the zymogen molecule. In line with this, zymogen
titers were usually one dilution (titer) step higher than
anti-proteinase titers in the same samples. This finding
agrees with preliminary data indicating that anti-zymogen
Table 2. Initial antistreptococcal antibody titers
Anti-zymogen Anti-proteinase Anti-streptolysin O Anti-DNAse B
Venezuela
APSGN 12.26 6 1.77 (N 5 102)a 11.28 6 1.45 (N 5 86)a 8.29 6 0.95 (N 5 58)a 9.17 6 1.31 (N 5 59)a
Strep pharyngitis 8.87 6 1.56 (N 5 9) 8.81 6 1.56 (N 5 9) 8.20 6 0.77 (N 5 9) 8.16 6 1.69 (N 5 9)
Controls 8.79 6 1.09 (N 5 61) 9.91 6 1.67 (N 5 58) 7.80 6 0.44 (N 5 45) 7.50 6 1.05 (N 5 45)
Chile
APSGN 13.44 6 1.44 (N 5 20)a 12.79 6 1.42 (N 5 20)a 8.49 6 1.05 (N 5 20) 8.25 6 1.27 (N 5 13)
Impetigo 12.07 6 1.79 (N 5 14)b 10.52 6 2.09 (N 5 14) 8.56 6 0.87 (N 5 14) 8.23 6 1.53 (N 5 14)
Controls 9.14 6 1.27 (N 5 10) 9.04 6 1.27 (N 5 10) 7.76 6 0.35 (N 5 8) 7.35 6 0.68 (N 5 8)
Argentina
APSGN 11.58 6 1.54 (N 5 31)a 10.34 6 1.56 (N 5 20)a
Controls 8.87 6 0.97 (N 5 22) 5.62 6 0.97 (N 5 23)
Abbreviations are in Table 1.
Values represent the mean log2 6 SD of the highest positive dilution. N is the number of individuals tested in each group. Titers of anti-zymogen in
APSGN patients in Chile are higher than in Argentina and Venezuela (P , 0.01). Anti-DNAse B titers are higher (P , 0.05) in APSGN patients in
Venezuela than in Chile. Differences in antibody titers between control groups in different countries are not significant (P . 0.05).
a P , 0.001 vs. corresponding control group
b P , 0.05 vs. corresponding control group
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Fig. 1. Individual anti-zymogen titers in patients with poststreptococcal
glomerulonephritis, control individuals and streptococcal infections in
Venezuela (A), Chile (B) and Argentina (C). Geometrical means are
shown as a straight line. Statistical significance of the differences are
shown in Table 2. Abbreviation URI is upper respiratory infection.
Fig. 2. Anti-streptolysin O titers (A) and anti-DNAse B titers (B and C)
in patients with acute poststreptococcal glomerulonephritis, controls and
streptococcal infections. Anti-streptolysin O titers are shown for Venezu-
ela and Chile together as data from these two countries can be compared
(Table 2). Geometrical means are shown as a straight line. Statistical
significance of the differences are shown in Table 2.
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titers were more frequently elevated in patients with
APSGN [14].
Increased antibody titers in individuals without apparent
infection could result from subclinical infection or from a
healed streptococcal infection. There were significant dif-
ferences in the antibody titers observed in streptococcal
infections not associated with nephritis. Chilean patients
with pyodermitis had antibody levels to zymogen and
proteinase approaching those seen in patients with APSGN
(Table 2). It seems likely that streptococci infecting the skin
of these children produce zymogen and host factors other
than levels of antibody response determine the rate and
degree of development of nephritis.
The lowest levels of antibodies to zymogen were seen in
Venezuelan patients with pharyngitis, who had titers com-
parable to those in the control group (Table 2). The group
A streptococcal etiology of the pharyngitis was reasonably
assured because all had a very florid clinical picture with
fever, tonsilar exudate and tender, enlarged regional lymph
nodes, a combination that is associated with streptococcal
etiology in about 90% of the cases [15, 17]. In addition,
positive identification of group A streptococci was done
with the help of a commercially available, widely used in
vitro test (testpack Strep A Plusy) that has a sensitivity of
90% and a specificity of 96% [18]. It is very unlikely that
systematic differences in the humoral immune responses
between the groups of patients were involved. The quanti-
ties of zymogen/proteinase produced during infection ap-
pear to be the governing factor.
It is probable, but not verified, that all b-hemolytic,
group A streptococci have the gene coding for zymogen; no
information is available on specific mechanisms of expres-
sion of this gene. We have tested a number of group A
isolates and all produced zymogen in fluid medium, but the
quantities varied greatly (unpublished observations). In
culture, production of zymogen is very sensitive to pH
Fig. 3. Serial determinations of anti-zymogen.
Number of patients tested on admission, and
one month and two months afterwards, are
shown for the corresponding country.
Interrupted line shows the level of 1 SD above
the mean in control individuals (2 SD above the
mean are 11.00).
Table 3. Antibody titers in patients with acute poststreptococcal nephritis (APSGN) and control (C) children
Titers
$1:dil
Venezuela
Zymogen Proteinase ASO DNAse B
APSGN
(N 5 102)
C
(N 5 61)
APSGN
(N 5 86)
C
(N 5 58)
APSGN
(N 5 58)
C
(N 5 45)
APSGN
(N 5 59)
C
(N 5 45)
100 102 61 86 58 57 45 56 36
200 102 61 86 58 54 45 52 21
400 102 40 85 49 24 5 43 7
800 96 20 82 35 7 0 24 2
1600 89 9 67 27 1 3 0
3200 74 1 43 9 0 0
6400 50 0 23 8
12800 33 11 2
25000 19 1 0
50000 4 0
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changes. Maximal synthesis occurred at pH 5.9, whereas
maximal growth was seen at pH 7.3, as reported by others
[6]. Therefore, it is to be expected that the site and duration
of infection will have a decisive influence on the total
quantity of zymogen produced. Unfortunately, in the cur-
rent study, no isolates from the patients were available for
study at the DNA and gene expression levels.
Despite the difficulties in comparing results separately
for different countries, there were no apparent differences
in the anti-zymogen reactivity in the patients with APSGN
associated with throat or with skin infections in the current
study. In Venezuela and in Argentina the anti-zymogen
titers in APSGN patients secondary to pharyngitis were
comparable to the titers in APSGN secondary to impetigo
(Results). In Chile there were only two patients with
APSGN secondary to pharyngitis (Table 1) and, therefore,
comparison with impetigo-associated nephritis in this coun-
try could not be made.
As expected, the serial antibody determinations demon-
strated a progressive decrease of anti-zymogen titers in
patients with APSGN. Yet, two months after the acute
episode, the mean titers remained at least 1 SD higher than
those seen in controls (Fig. 3). This finding is in agreement
with the report of Cu and Zabriskie [13], who found that
anti-proteinase titers were still elevated three months after
the acute episode.
There are several ways of approaching the serological
diagnosis of streptococcal infection. The “upper limit of
normal” of antibody titers varies in different populations,
as well as with age and laboratory [19–23]. The 80th
percentile in normals is the level frequently used to define
Table 3. Continued
Titers
$1:dil
Chile Argentina
Zymogen Proteinase ASO DNAse B Zymogen Proteinase
APSGN
(N 5 20)
C
(N 5 10)
APSGN
(N 5 20)
C
(N 5 10)
APSGN
(N 5 21)
C
(N 5 12)
APSGN
(N 5 14)
C
(N 5 8)
APSGN
(N 5 31)
C
(N 5 22)
APSGN
(N 5 20)
C
(N 5 23)
100 20 10 20 9 20 8 13 8 31 22 20 2
200 20 10 20 9 19 8 10 2 31 16 20 0
400 20 7 19 9 14 1 7 0 29 9 19
800 20 5 19 7 7 0 3 26 2 14
1600 19 3 19 0 0 0 20 0 14
3200 19 0 19 9 3
6400 18 16 4 3
12800 14 11 3 1
25000 7 0 0 0
50000 3
Numbers correspond to the patients with a corresponding or higher antibody titer. Titers selected for the table were those from the anti-zymogen
assay. Numbers in parenthesis indicate the total number of patients tested.
Table 4. Likelihood ratios of anti-zymogen and anti-proteinase titers
Titers
(1:dilution)
Venezuela Chile Argentina
Zymogen Proteinase Zymogen Proteinase Zymogen Proteinase
$200 1.00 1.00 1.00 1.11 1.38 11.5
$400 1.53 1.17 1.43 1.06 2.29 —
$800 2.87 1.58 2.00 1.36 9.22 —
$1600 5.91 1.67 3.17 — — —
$3200 44.2 3.23 — — — —
Likelihood ratios for titers higher than 3200 and those left blank could not be calculated because of inappropriate values (division by zero).
Fig. 4. Receiver operating characteristics (ROC) curve for the four
antibody tests on samples from Venezuela. Anti-zymogen and antipro-
teinase curves are drawn with uninterrupted lines. Anti-zymogen titers are
superior to the rest at all levels of the curve. Symbols are: (f) anti-
zymogen; (E) anti-DNAseB; () anti-proteinase; (M) anti-streptolysin.
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the “upper limit” of normal. In the case of ASO titers, this
level may miss more than 30% of true streptococcal
infections [23]. With respect to anti-zymogen titers, the 80th
percentile in controls corresponds to titers of 1:800 in
Venezuela, and thus the use of this upper limit of normal
would result in a failure to detect 11.7% of the cases of
APSGN. More important, dichotomous methods assign the
same diagnostic value to all titers above or below the cutoff
level. Therefore, as elegantly discussed by Gray et al [23],
more useful information can be obtained from the likeli-
hood ratio (Table 4), which provides a ratio of the odds of
infection to the odds of no infection for every level of
antibody response. This information is of clinical impor-
tance when a patient presents with acute glomerulonephri-
tis and a streptococcal etiology needs to be confirmed or
ruled out from a single antibody determination.
Sensitivity and specificity values derived from the data
shown in Table 3, as well as likelihood ratios shown in
Table 4, can be used to calculate the predictive values, both
negative and positive, of a given antibody titer, if the prior
(pre-test) probability of nephritogenic streptococcal infec-
tion is known. For example, 80% of the acute glomerulo-
nephritis diagnosed in children in the University Hospital
of Maracaibo are poststreptococcal [24]. Therefore, anti-
zymogen titers of 1:3200 in a child with an acute nephritic
syndrome (TPR 5 0.73, TNR 5 0.98, from data for
Venezuela in Table 3) would have a predictive value
positive of 99% for streptococcal etiology. In contrast, an
anti-zymogen titer of 1:800 in the same patient (TPR 5
0.94, TNR 5 0.67) would have a predictive value negative
of 74% for streptococcal etiology.
Another example of the clinical usefulness of predictive
values is found in the study of families of patients with
APSGN. Prospective studies in Maracaibo have shown that
79% of the parents and 95% of the siblings of index cases
of APSGN have streptococcal infection, presumably ne-
phritogenic [25]. From the data shown in Table 3, it may be
calculated that anti-zymogen titers of 1:800 have a negative
predictive value of 75% in parents and 37% in siblings of
patients with APSGN.
As demonstrated by the ROC curves shown in Figure 4,
increased anti-zymogen antibody titers are the best avail-
able marker of nephritogenic streptococcal infection. Anti-
proteinase titers are comparable to ASO titers and anti-
DNAse B titers are superior to ASO and anti-proteinase
titers. Since the lines do not cross, it is apparent that
anti-zymogen titers offer the best combination of true and
false positive rates at all levels of the curve.
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APPENDIX
Abbreviations used in this article are: APSGN, acute poststreptococcal
glomerulonephritis; ASO, anti-streptolysin; ROC, receiver operating
characteristic; TNR, true negative rate; TPR, true positive rate.
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